Revenue for the year was a record $452.3 million, an increase of 30%. Cochlear implant unit sales growth of 19% to 12,901 drove the increase in revenue together with the Nucleus Freedom release late last year and a full year of Baha product sales following the acquisition of Entific Medical Systems in March 2005. Earnings before interest and taxes (EBIT) of $111.5 million increased by 35% and was 25% of revenue. Net profit attributable to equity holders of the parent of $80.0 million increased 34% from last financial year. Basic earnings per share (EPS) increased by 33% to 146.8 cents per share. Core earnings (expensing all development costs as incurred and excluding amortisation of acquired intangible assets and share based compensation) were at a record $86.4 million. Core basic EPS increased by 41% to 158.4 cents per share. The directors declared a final dividend of 55.0 cents per share, which will be paid on 21 September 2006. This brings the full year’s dividend to $1.00 per share, fully franked, 25% up on last year. The Nucleus Freedom had a full year of sales in this year and is now rolled out in the major markets.There was great uptake of this market-leading product during the year. Clinical results for the Freedom system are now available and show a significant improvement in speech performance in quiet and noisy situations which has helped drive the sales of the system. The Entific Medical Systems business was integrated during the year and revenue growth was maintained at 30% assuming Cochlear owned the business for the entire year last year. Cochlear continued to roll out systems to support growth. During 2006, Oracle enterprise resource planning (ERP) system was implemented in the Americas region. It will begin to implement Oracle in Europe as well as convert manufacturing to Oracle in 2007. Manufacturing capability was improved through the continued implementation of “Lean Manufacturing” principles.